Indian Journal of Tuberculosis最新文献_第10页

Counseling intervention improves treatment adherence among newly diagnosed drug sensitive Tuberculosis patients of Ahmedabad city – A mixed methods approach 咨询干预改善艾哈迈达巴德市新诊断的药物敏感结核病患者的治疗依从性——一种混合方法

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2023.03.005

Devang Raval , Parimal Patel , Radhika Sharma , Kalpita Shringarpure

{"title":"Counseling intervention improves treatment adherence among newly diagnosed drug sensitive Tuberculosis patients of Ahmedabad city – A mixed methods approach","authors":"Devang Raval , Parimal Patel , Radhika Sharma , Kalpita Shringarpure","doi":"10.1016/j.ijtb.2023.03.005","DOIUrl":"10.1016/j.ijtb.2023.03.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Counselling sessions based on the health behaviour module for patients on TB treatment<span><span> may help improve the level of understanding of tuberculosis and its treatment, importance of adherence to therapy, possible side effects, dietary habits and to address any misconceptions; leading to better adherence and improved outcome. Hence, study attempted to assess the impact of brief counselling intervention through treatment adherence supportive activist (TASA) in improving adherence to treatment among </span>drug sensitive TB patients.</span></p></div><div><h3>Methods</h3><p>An explanatory mixed methods design (QUAN-Qual) was carried out. Out of 23 Tuberculosis units (TUs) in Ahmedabad Municipal Corporation (AMC) two were selected, one interventional group where trained counsellor was recruited while other was the control group. All drug sensitive TB patients diagnosed at both selected TUs during January to March 2020 were included in the study. Among all patients who were non-adherent in both the TUs, 14 were selected to explore factors contributing to non-adherence to treatment.</p></div><div><h3>Results</h3><p>At the end of intensive phase, drug adherence in the study TU was 85.71% while it was 67.5% in the control TU. At the end of one month of treatment, the proportion of patients having better level adherence was more among counselled patients as compared to non-counselled patients. Marital status, religion, gender did not affect the level of adherence. Reasons for non-adherence as well as perceived barriers to adherence to TB treatment were treatment related, patient related and social barriers.</p></div><div><h3>Conclusion</h3><p>Dedicated NTEP counsellor (TASA) can help improve the treatment adherence and impact of physical counselling.</p></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"71 1","pages":"Pages 19-26"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48639207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tuberculosis of head and neck region, our experience at a tertiary care center in Gujarat 头颈部结核病，我们在古吉拉特邦三级护理中心的经验

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2023.03.006

Niral Modi, Ishita Shah, Priyanshi Shah, Chandni Bhatt, Apoorva Jain

{"title":"Tuberculosis of head and neck region, our experience at a tertiary care center in Gujarat","authors":"Niral Modi, Ishita Shah, Priyanshi Shah, Chandni Bhatt, Apoorva Jain","doi":"10.1016/j.ijtb.2023.03.006","DOIUrl":"10.1016/j.ijtb.2023.03.006","url":null,"abstract":"<div><h3>Background</h3><p><span>Head and neck lesions of tuberculosis, though not uncommon are often difficult to diagnose and require a unique management protocol. These lesions are often misdiagnosed as bacterial infections, malignancies<span> or other granulomatous diseases. Hence in our study we endeavor to gain a better understanding of the diagnostic and management protocols of tuberculosis in </span></span>otorhinolaryngology.</p></div><div><h3>Methods</h3><p>We have performed an observational study at our institute, the patient’s details were obtained from patient record forms and noted in a standard proforma. Results were calculated as percentage and Chi square analysis was performed.</p></div><div><h3>Results</h3><p>We found cervical tuberculous lymphadenitis<span> to be the most common manifestation 76.97%, with a significant association with pulmonary tuberculosis. Neck swelling was the most common presenting complaint, 65.35%. 26–50 years of age was the most commonly involved age group.</span></p></div><div><h3>Conclusion</h3><p>FNAC, PCR and histopathology are the modalities for bacteriological diagnosis for tuberculosis of Head and Neck. Anti-tuberculous therapy is uniformly found to be useful in all the patients, with surgical intervention used as and when required.</p></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"71 1","pages":"Pages 27-29"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46698549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From nature's bounty to drug discovery: Leveraging phytochemicals and molecular approaches to combat multi-drug-resistant (MDR) tuberculosis 从大自然的慷慨到药物的发现：利用植物化学物质和分子方法对抗耐多药结核病

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2023.08.007

{"title":"From nature's bounty to drug discovery: Leveraging phytochemicals and molecular approaches to combat multi-drug-resistant (MDR) tuberculosis","authors":"","doi":"10.1016/j.ijtb.2023.08.007","DOIUrl":"10.1016/j.ijtb.2023.08.007","url":null,"abstract":"<div><p>A large number of people annually lose their lives to tuberculosis (TB), which is an age-old disease caused by the <em>Mycobacterium tuberculosis</em>. The global spread of TB is a concern for all regions. The south-east Asian region recorded 46% of all new TB cases in 2021, followed by the African and western Pacific regions with 23% and 18%, respectively. Researchers are always searching at natural substances for potential alternative therapeutics to tackle the worrisome growth in multi-drug-resistant (MDR) tuberculosis due to the high costs associated with developing new treatments and unfavourable side effects of currently used synthetic pharmaceuticals. Phytochemicals show promising results as a future health aid due to their multi-targeting ability on pathogen cells. In the search for new drug leads, the Ayurvedic and Siddha medical systems have made an extensive use of ethnomedicinal tools, including the use of plants like Amalaki (<em>Emblica officinalis</em> Gaertn.), Guduchi (<em>Tinospora cordifolia</em> willd.), Sariva (<em>Hemidesmus indicus</em> R.Br.), Kustha (<em>Saussurea lappa</em> Falc.), turmeric (<em>Curcuma longa</em> Mal.) and Green tea (<em>Camellia sinensis</em> Linn.). These sources are high in flavonoids, polyphenols, tannins and catechins, has been shown to reduce the risk of TB. In this overview, we look at how natural sources like plants, algae and mushrooms have helped researchers to find new drug leads, and how to back these natural sources through mapping the molecular approaches and other approaches has helped them to defeat MDR.</p></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"71 ","pages":"Pages S117-S129"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41787814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MDR TB: New drugs, research and policy 耐药结核病：新药、研究和政策

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2024.06.005

引用次数: 0

Update on drug-resistant pulmonary tuberculosis treatment in hemodialysis patients 血液透析患者耐药肺结核治疗进展

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2023.04.011

{"title":"Update on drug-resistant pulmonary tuberculosis treatment in hemodialysis patients","authors":"","doi":"10.1016/j.ijtb.2023.04.011","DOIUrl":"10.1016/j.ijtb.2023.04.011","url":null,"abstract":"<div><p><span>World Health Organization (WHO) issued the latest recommendations regarding the management of drug-resistant Tuberculosis (TB) in 2022, allowing the replacement of ethambutol<span><span> (6 months) with linezolid (2 months). This recommendation also introduced a new regimen, namely </span>bedaquiline<span><span>, pretomanide, linezolid, moxifloxacin<span> (BPaLM) for fluoroquinolone-sensitive patients and bedaquiline, pretomanide, linezolid, (BPaL) for patients insensitive to fluoroquinolone (6–9 months). The latest TB regimen introduced by WHO provides a shorter-course treatment, however not much has been discussed about the impact of this new regimen on </span></span>chronic kidney disease<span><span> (CKD) patients, particularly on hemodialysis (HD). The condition of CKD can interfere with the </span>pharmacokinetics of TB medication, thus could reduce effectiveness and increase toxicity. The drugs used on this new regimen are mostly safe for renal impairment patients due to the dominant metabolism in the liver. Particular precaution is given to the administration of linezolid due to increased </span></span></span></span>hematology side effects and bedaquiline with the side effect of QTC interval lengthening and increased risk of arrhythmias. Although this regimen research has not been in many studies in renal failure patients, no significant side effects nor kidney damage evidence was found. This remains to be proven by more research on the patient population with renal failure.</p></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"71 ","pages":"Pages S110-S116"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43229115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathways to end TB- challenges 终结结核病之路--挑战

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2024.01.008

V.K. Arora, Kamal Kishore Chopra

引用次数: 0

Beyond the norm: Primary multidrug-resistant extrapulmonary tuberculosis unveiled in a case series 超越常规：在一个病例系列中揭示的原发性耐多药肺外结核病

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2024.03.010

引用次数: 0

Mutational analysis in drug resistant Mycobacterium tuberculosis in Western Uttar Pradesh 北方邦西部耐药结核分枝杆菌的突变分析

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2024.01.009

{"title":"Mutational analysis in drug resistant Mycobacterium tuberculosis in Western Uttar Pradesh","authors":"","doi":"10.1016/j.ijtb.2024.01.009","DOIUrl":"10.1016/j.ijtb.2024.01.009","url":null,"abstract":"<div><h3>Background</h3><p><span>Multi-drug resistant tuberculosis (MDR-TB) results in treatment failure and poor clinical outcomes. This study was carried out with the aim to determine the pattern of drug resistance against </span><span><em>Mycobacterium tuberculosis</em></span><span> towards first line ATT (anti-tubercular treatment) in sputum smear–positive patients using Line Probe Assay (LPA).</span></p></div><div><h3>Methods</h3><p><span>A cross sectional prospective study was carried out in a tertiary care Hospital of Meerut. A total of 898 sputum samples (on spot and early morning) collected from 449 suspected pulmonary tuberculosis patients as per RNTCP guidelines were screened by microscopy. Decontamination was done by N-acetyl-</span><span>l</span><span>-cysteine and sodium hydroxide<span>. Then smear positive samples were subjected to 1st line drug susceptibility testing (DST) using LPA GenoType® MTBDRplus (HAIN Life Science) assay, a molecular method which allows rapid detection of Rifampicin (Rif) and Isoniazid (INH) resistance.</span></span></p></div><div><h3>Results</h3><p>The overall burden of MDR TB in this geographical area was 7.9 %. Mono-resistance with Rif alone was around 2.8 %. However, the mono-resistance with INH (inhA gene) and INH (katG gene) was 2.8 % and 1.1 % respectively. Drug resistance of Rif was due to mutations in rpoB gene while resistances to INH were more commonly due to mutation in inhA gene followed by katG gene. TB was more commonly seen in the age group of 30–59 years (43.8 %) and predominantly in males.</p></div><div><h3>Conclusion</h3><p>Tuberculosis positivity rate is high in Western Uttar Pradesh. Burden of MDR TB in Western Uttar Pradesh was similar to National data. Line probe assay can be used as a primary method to diagnose multi drug resistant TB as done in present study which can help in earlier initiation of correct therapy.</p></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"71 ","pages":"Pages S77-S80"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139637878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Longer the Therapy, the Worse the Severity of the Adverse Drug Reactions that Occur in Drug-Resistant Pulmonary Tuberculosis Patients 耐药肺结核患者治疗时间越长，药物不良反应的严重程度越严重

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2024.06.001

{"title":"The Longer the Therapy, the Worse the Severity of the Adverse Drug Reactions that Occur in Drug-Resistant Pulmonary Tuberculosis Patients","authors":"","doi":"10.1016/j.ijtb.2024.06.001","DOIUrl":"10.1016/j.ijtb.2024.06.001","url":null,"abstract":"<div><h3>Background</h3><p>It is estimated that drug-resistant (DR) Tuberculosis (TB) (DR-TB) patients in Indonesia are 2.40% of all new TB patients and 13% of previously treated TB patients with a total incidence of DR-TB cases of 24,000 people. The adverse drug reactions (ADRs) of DR-TB are still a problem that can certainly affect the success of therapy. The aim of this study was to determine the correlation between the length of therapy and regimen therapy of DR-TB with the severity of ADRs.</p></div><div><h3>Methods</h3><p>Data collection was carried out retrospectively on the medical records of DR-TB patients in 2020–2021 and sampling used a purposive sampling technique that complied with the inclusion criteria.</p></div><div><h3>Results</h3><p>Of the 86 patients, the majority of DR-TB patients in X Hospital were 26–45 years old 35 (40.7%), 52 (60.5%) male, the most common comorbid was type II DM, 19 (22.1%), and the most nutritional status was malnutrition as much as 39 (45.3%). The most common type of ADR was hyperuricemia in 31 (36.0%). The results of the correlation analysis showed that there was a relationship between the length of therapy and the severity of ADRs (ρ = 0.002) and there was no relationship between the type of therapy regimen and the severity of ADRs (ρ = 0.184).</p></div><div><h3>Conclusion</h3><p>The longer DR-TB therapy, the higher the severity of ADRs and there is no relationship between the type of therapy regimen and the severity of ADRs.</p></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"71 ","pages":"Pages S97-S100"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141396463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Favorable clinical outcomes and anti-mycobacterial efficacy of pretomanid in patients with highly resistant tuberculosis: A review 耐药性强的肺结核患者使用普托玛尼的良好临床效果和抗霉菌疗效：综述

Indian Journal of Tuberculosis Pub Date : 2024-01-01 DOI: 10.1016/j.ijtb.2023.09.011

{"title":"Favorable clinical outcomes and anti-mycobacterial efficacy of pretomanid in patients with highly resistant tuberculosis: A review","authors":"","doi":"10.1016/j.ijtb.2023.09.011","DOIUrl":"10.1016/j.ijtb.2023.09.011","url":null,"abstract":"<div><p><span><span>Rising cases of drug resistance of mycobacterium species are one of the biggest concerns when the goal is to eradicate TB (Tuberculosis) from the world by the year 2030. A limited number of </span>treatment options as MTB (</span><span><em>Mycobacterium tuberculosis</em></span><span><span>) is getting resistant to anti-mycobacterial drugs either due to a patient's non-compliance towards treatment regimen or if a patient is infected by drug-resistant species of MTB. This review aims to assess the effectiveness of pretomanid, a recently approved drug for the treatment of extensively drug-resistant TB. A thorough search of databases like PubMed, Cochrane library, CDC, Research Gate, and Google scholar was used in order to find case reports and </span>clinical trials<span> providing data on the efficacy of pretomanid in different drug regimens. According to research trials conducted, the drug appears to be efficacious, safe, and well-tolerable. Only headache was the most frequently observed adverse drug event, and a high dose-related increase in serum creatinine level was seen, which came to normal after the drug was discontinued.</span></span></p></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"71 ","pages":"Pages S130-S135"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136093087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0